These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32446432)

  • 1. Imaging and Management of Prostate Cancer.
    Surasi DSS; Chapin B; Tang C; Ravizzini G; Bathala TK
    Semin Ultrasound CT MR; 2020 Apr; 41(2):207-221. PubMed ID: 32446432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiparametric (mp) MRI of prostate cancer.
    Kumar V; Bora GS; Kumar R; Jagannathan NR
    Prog Nucl Magn Reson Spectrosc; 2018 Apr; 105():23-40. PubMed ID: 29548365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies.
    Wegelin O; Exterkate L; van der Leest M; Kummer JA; Vreuls W; de Bruin PC; Bosch JLHR; Barentsz JO; Somford DM; van Melick HHE
    Eur Urol; 2019 Apr; 75(4):582-590. PubMed ID: 30522912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [
    Bauman G; Martin P; Thiessen JD; Taylor R; Moussa M; Gaed M; Rachinsky I; Kassam Z; Chin J; Pautler S; Lee TY; Valliant JF; Ward A
    Eur Urol Focus; 2018 Sep; 4(5):702-706. PubMed ID: 28753797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging.
    Al-Bayati M; Grueneisen J; Lütje S; Sawicki LM; Suntharalingam S; Tschirdewahn S; Forsting M; Rübben H; Herrmann K; Umutlu L; Wetter A
    Urol Int; 2018; 100(2):164-171. PubMed ID: 29393268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
    Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
    Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous
    Eiber M; Weirich G; Holzapfel K; Souvatzoglou M; Haller B; Rauscher I; Beer AJ; Wester HJ; Gschwend J; Schwaiger M; Maurer T
    Eur Urol; 2016 Nov; 70(5):829-836. PubMed ID: 26795686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer.
    Panebianco V; Valerio MC; Giuliani A; Pecoraro M; Ceravolo I; Barchetti G; Catalano C; Padhani AR
    Eur Urol Oncol; 2018 Aug; 1(3):208-214. PubMed ID: 31102623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
    Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
    Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidance of treatment decisions in risk-adapted primary radiotherapy for prostate cancer using multiparametric magnetic resonance imaging: a single center experience.
    Panje C; Panje T; Putora PM; Kim SK; Haile S; Aebersold DM; Plasswilm L
    Radiat Oncol; 2015 Feb; 10():47. PubMed ID: 25880635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiparametric prostate MRI: focus on T2-weighted imaging and role in staging of prostate cancer.
    Gupta RT; Spilseth B; Patel N; Brown AF; Yu J
    Abdom Radiol (NY); 2016 May; 41(5):831-43. PubMed ID: 27193786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic accuracy of
    Scheltema MJ; Chang JI; Stricker PD; van Leeuwen PJ; Nguyen QA; Ho B; Delprado W; Lee J; Thompson JE; Cusick T; Spriensma AS; Siriwardana AR; Yuen C; Kooner R; Hruby G; O'Neill G; Emmett L
    BJU Int; 2019 Nov; 124 Suppl 1():42-49. PubMed ID: 31287613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography for prostate, bladder, and renal cancer.
    Schöder H; Larson SM
    Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
    Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
    BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of prostate multiparametric MRI for prediction of prostate cancer extra-prostatic extension according to NCCN risk categories: implication for surgical planning.
    Falagario UG; Jambor I; Ratnani P; Martini A; Treacy PJ; Wajswol E; Lantz A; Papastefanou G; Weil R; Phillip D; Lewis S; Haines K; Cormio L; Carrieri G; Kyprianou N; Wiklund P; Tewari AK
    Minerva Urol Nefrol; 2020 Dec; 72(6):746-754. PubMed ID: 32182231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy.
    Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Pennisi M; Morgia G
    Scand J Urol; 2017 Aug; 51(4):260-263. PubMed ID: 28513296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiparametric Magnetic Resonance Imaging Features Identify Aggressive Prostate Cancer at the Phenotypic and Transcriptomic Level.
    Beksac AT; Cumarasamy S; Falagario U; Xu P; Takhar M; Alshalalfa M; Gupta A; Prasad S; Martini A; Thulasidass H; Rai R; Berger M; Hectors S; Jordan J; Davicioni E; Nair S; Haines K; Lewis S; Rastinehad A; Yadav K; Jayaratna I; Taouli B; Tewari A
    J Urol; 2018 Dec; 200(6):1241-1249. PubMed ID: 30563651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.